Graves Disease Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Graves' disease is an autoimmune condition and the most common cause of hyperthyroidism, characterized by excessive production of thyroid hormones. The global Graves' disease market encompasses the diagnosis and treatment of this condition, including antithyroid drugs, radioactive iodine therapy, thyroidectomy, and management of associated complications such as thyroid eye disease.

• •Global market valued at approximately $2.3 billion in 2025, with growth projected at a CAGR of 3.54% through 2036
• •The seven major markets (7MM) alone reached approximately $4.7 billion in 2025, reflecting the concentration of value in developed economies
• •Market encompasses antithyroid medications, radioactive iodine, surgical interventions, and management of thyroid eye disease

Rising global prevalence of autoimmune and thyroid disorders is a primary driver of market expansion, as improved diagnostic capabilities lead to higher detection rates. An aging population, greater healthcare access in emerging economies, and increased awareness of thyroid disorders are further fueling demand for treatment options across all regions.

• •Increasing prevalence of autoimmune diseases and thyroid disorders worldwide contributes to a growing patient pool
• •Improved diagnostic technologies and heightened clinical awareness enable earlier and more widespread disease detection
• •Aging global population and rising healthcare expenditure support sustained demand for Graves' disease treatments

The market is segmented by treatment type, antithyroid medications, radioactive iodine therapy, and surgical procedures, as well as by end user, including hospitals, specialty clinics, and homecare settings. Geographically, North America commands the largest share due to high disease prevalence, advanced healthcare infrastructure, and strong pharmaceutical R&D activity.

• •Treatment-based segmentation includes antithyroid drugs (methimazole, propylthiouracil), radioactive iodine ablation, and thyroidectomy
• •End-user segments span hospitals, specialty endocrine clinics, and homecare settings
• •North America leads globally, followed by Europe, with Asia-Pacific representing the fastest-growing regional market

What are the recent trends and outlook?

The market is expected to reach between $2.87 billion and over $5 billion by 2032-2036 depending on scope and methodology, reflecting varying estimates across industry analyses. Emerging trends include the development of long-acting antithyroid agents, biologic treatments for thyroid eye disease, and a growing emphasis on personalized medicine approaches tailored to individual patient profiles and disease severity.

• •Introduction of biologic therapies targeting thyroid eye disease, such as teprotumumab and emerging pipeline candidates, is reshaping the treatment landscape
• •Precision medicine and biomarker-driven treatment personalization are gaining clinical and commercial traction
• •Market growth expected to continue through 2036, with expansion in both established and emerging markets as access to specialty endocrine care improves